FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Bao, Xiu Qi ^a   Li, Ning ^a   Wang, Tao ^b   Kong, Xiang Chen ^c   Tai, Wen Jiao ^a   Sun, Hua ^a   Zhang, Dan ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b Second Hospital Beijing Municipal Corps Chinese People's Armed Police Forces   (China)

^c Shenzhen University Health Science Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; GLYCOGEN SYNTHASE KINASE 3BETA; N [2 (4 HYDROXYPHENYLETHYL)] 2 (2,5 DIMETHOXY PHENYL) 3 (3 METHOXY 4 HYDROXYPHENYL) ACRYLAMIDE; NEUROPROTECTIVE AGENT; PROTEIN KINASE B; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SPATIAL LEARNING; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; APOPTOSIS; ASPARTIC ACID ENDOPEPTIDASES; BENZENEACETAMIDES; CASPASE 3; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; ESCAPE REACTION; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; HUMANS; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PHENOLS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84892389055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078033     Document Type: Article

References (31)

1. Edbaue D, Winkler E, Regula JT, Pesold B, Steiner H, et al. (2003) Reconstitution of gamma-secretase activity. Nat Cell Biol 5: 486-488.
2. Harmeier A, Wozny C, Rost BR, Munter LM, Hua H, et al. (2009) Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. J Neurosci 29: 7582-7590.
3. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, et al. (2005) The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33: 1087-1090.
4. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, et al. (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28: 4231-4237.
5. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
6. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7: 656-664.
7. Citron M (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9: 387-398.
8. Bao XQ, Kong XC, Liu GT (2010) The novel cyclic squamosamide derivative FLZ improves memory deficits in aged mice and the mechanisms. Chin J New Drug 19: 867-872.
9. Fang F, Liu G (2007) A novel cyclic squamosamide analogue compound FLZ improves memory impairment in artificial senescence mice induced by chronic injection of D-galactose and NaNO2. Basic Clin Pharmacol Toxicol 101: 447-454.
10. Fang F, Liu GT (2008) Novel squamosamide derivative (compound FLZ) attenuates Abeta25-35-induced toxicity in SH-SY5Y cells. Acta Pharmacol Sin 29: 152-160.
11. Hou J, Qu F, Wu C, Ren Q, Zhang J (2012) Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 66: 232-239.
12. Ding Y, Qiao A, Wang Z, Goodwin JS, Lee ES, et al. (2008) Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci 28: 11622-11634.
13. Yu Y, He J, Zhang Y, Luo H, Zhu S, et al. (2009) Increased hippocampal neurogenesis in the progressive stage of Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus 19: 1247-1253.
14. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, et al. (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739: 198-210.
15. Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez-Mejias E, et al. (2011) Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J Biol Chem 286: 18414-18425.
16. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
17. Lemere CA (2009) Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog Brain Res 175: 83-93.
18. Kerchner GA, Boxer AL (2010) Bapineuzumab. Expert Opin Biol Ther 10: 1121-1130.
19. Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, et al. (2011) Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier. Mol Med 17: 149-162.
20. Fang F, Liu GT (2006) Protective effects of compound FLZ on beta-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment. Acta Pharmacol Sin 27: 651-658.
21. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, et al. (2003) APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163: 83-95.
22. Ghosh AK, Gemma S, Tang J (2008) beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 5: 399-408.
23. Hou Y, Yu YB, Liu G, Luo Y (2009) A natural squamosamide derivative FLZ reduces amyloid-beta production by increasing non-amyloidogenic AbetaPP processing. J Alzheimers Dis 18: 153-165.
24. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R (2011) Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res 8: 659-665.
25. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, et al. (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31: 165-170.
26. Luan K, Rosales JL, Lee KY (2012) Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation. Ageing Res Rev 12: 174-181.
27. Kurt MA, Davies DC, Kidd M, Duff K, Howlett DR(2003) Hyperpho-sphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol Dis 14: 89-97.
28. Kulic L, Kurosinski P, Chen F, Tracy J, Mohajeri M H, et al. (2006) Active immunization trial in Abeta42-injected P301L tau transgenic mice. Neurobiol Dis 22: 50-56.
29. Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, et al. (2008) Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci 28: 12163-12175.
30. Avila J (2006) Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett 580: 2922-2927.
31. Zhang Z, Zhao R, Qi J, Wen S, Tang Y, et al. (2011) Inhibition of glycogen synthase kinase-3beta by Angelica sinensis extract decreases beta-amyloid-induced neurotoxicity and tau phosphorylation in cultured cortical neurons. J Neurosci Res 89: 437-47.